Interleukin-7 (IL-7) and the IL-7 receptor (IL-7R) have been shown to be alternatively spliced in infectious diseases. We tested IL-7 and IL-7R splicing in a tuberculosis (TB)-vaccine/Mycobacterium tuberculosis (Mtb)-challenge model in non-human primates (NHPs). Differential IL-7 splicing was detected in peripheral blood mononuclear cells (PBMCs) from 15/15 NHPs showing 6 different IL-7 spliced isoforms. This pattern did not change after infection with virulent Mtb. We demonstrated increased IL-7 (6 exon) and IL-17 protein production in lung tissue along with concomitant decreased transforming growth factor-b (TGF-b) from NHPs (vaccinated with a recombinant BCG (rBCG)) who showed increased survival after Mtb challenge. IL-7 increased IL-17 and interferon-g (IFN-g) gene and protein expression in PBMCs. Mtb-infected NHPs showed differential IL-7R splicing associated with the anatomical location and tissue origin, that is, in lung tissue, hilus, axillary lymph nodes (LNs) and spleen. Differential splicing of the IL-7R was typical for healthy (non-Mtb infected) and for Mtb-infected lung tissue with a dominant expression of soluble IL-7R (sIL-7R) receptor lacking exon 6 (9:1 ratio of sIL-7R/cell-bound IL-7R). Differential ratios of cell-bound vs sIL-7R could be observed in hilus and axillary LNs from Mtb-infected NHPs with an inversed ratio of 1:9 (sIL-7R/cell-bound IL-7R) in spleen and PBMCs. Soluble IL-7R is exclusively present in lung tissue.
Introduction
The interleukin-7 (IL-7) and IL-7 receptor (IL-7R) axis plays a crucial role in immune cell differentiation and survival; [1] [2] [3] genetic deletions in IL-7 or IL-7R lead to a severe combined immunodeficiency phenotype. 4, 5 Both IL-7 and IL-7R have been shown to be alternatively spliced.
6-8 IL-7 is composed of six exons, and different IL-7 variants have been described in transformed cells and in human tissues. 6, 7, 9 IL-7d5, the isoform lacking exon 5, has been demonstrated to be dominantly expressed in granuloma lesions from individuals with latent tuberculosis. 7 This IL-7 isoform acts as an IL-7 agonist in promoting immune cell survival and differentiation of human thymocytes, and it also drives differentiation of human neuronal stem cells. 7, 10 More recently, the IL-7R has been demonstrated to be alternatively spliced associated with different haplotypes that affect gene regulation and potentially RNA splicing 8, 11 _ENREF_9. A particular haplotype has been associated with an increased risk of developing multiple sclerosis. Haplotype 2, associated with less soluble IL-7R (sIL-7R) production, appears to be protective against multiple sclerosis.
12,13 IL-7 and IL-7R may play a role in Mycobacterium tuberculosis (Mtb) infection at different levels: IL-7 drives maturation of antigen-presenting cells and ensures T-cell survival, 14, 15 whereas passive transfer of Mtb-reactive immune cells from IL-7-treated mice have been shown to prolong survival and reduce pulmonary Mtb load in mice. 16 The IL-7R is expressed by a variety of immune 17, 18 and non-immune cells, 7, 10 either along with the common cytokine g-chain 19 or the receptor for thymic stromal lymphopoietin on dendritic cells. 20 The soluble form of the IL-7R blocks IL-7 activity. It is unable to phosphorylate signal transducer and activator of transcription 5 and it has been demonstrated to be increased in serum from individuals with human immunodeficiency virus infection. Increased sIL-7R in serum from individuals with human immunodeficiency virus infection may therefore neutralize IL-7-mediated effects on T cells. 21, 22 The immune system creates diversity and responds to infection by various adaptive mechanisms, one of them being alternative splicing of cytokine gene products. 23 For instance, alternatively spliced IL-4, lacking exon 2, is produced in response to Mtb infection. 24 IL-4d2 represents a natural IL-4 antagonist by competing with IL-4 for binding to the nominal receptor. 25, 26 Increased IL-4d2 production may not only prevent allergic reactions and subsequent airway constriction, 27 but it also appears to be associated with the control of Mtb infection, 28 presumably because of preventing a dominant Th2 response. We examined in the current report the IL-7 and IL-7R splice pattern in peripheral blood mononuclear cells (PBMCs) and in situ (lung, spleen and LNs (lymph nodes)) in a tuberculosis non-human primate (NHP) model, which allowed to study differential IL-7 and IL-7R expression profiles in response to Mtb infection.
Results

IL-7 and IL-7R isoform patterns in PBMCs
Female rhesus macaques were divided into three groups and immunized with different tuberculosis (TB) vaccines (Bacillus Calmette-Guérin (BCG) and recombinant BCG (rBCG)), followed by a challenge with virulent Mtb bacilli. The analysis of PBMCs before immunization, and before and after Mtb challenge enabled to study IL-7 and IL-7R alternative splicing patterns in a control fashion in longitudinally sampled specimens. Group 1 received BCG immunization (SSI1331), group 2 an rBCG that overexpresses perfringolysin along with the antigens Ag85A/B and TB10.4, and group 3 received only saline. PBMCs from the animals were harvested at time point 0 (before vaccination) and at weeks 27 and 44 (that is, 4 weeks after Mtb challenge at week 39 after the first prime). First, we cloned and sequenced IL-7 and IL-7R from NHP PBMCs (Supplementary Figure S1a) . Five IL-7 variants could be detected in PBMCs: the six exonspanning canonical IL-7 and isoforms lacking either exon 3, exon 4, exons 4/5 or exons 3/4/5. Similar to human IL-7, we were able to detect IL-7 splice variants that show, in addition to exon skipping, a loss of 56 bp in exon 2 (Supplementary Figure S1a) . The latter three splice variants were not abundant and could not be visualized using the Agilent system (Agilent Technologies, Waldbronn, Germany), yet we could demonstrate their presence after subcloning the appropriate bands from the control gels (data not shown).
Three IL-7R variants could be identified in NHP PBMCs: the 8 exon-spanning canonical form and IL-7R variants lacking either exon 6 or exons 5/6 (Supplementary Figure S1b ). IL-7Rd5/6 expression was very low in PBMCs and only detectable directly in spleen tissue, confirmed by subcloning and DNA sequencing. The dominant (490%) IL-7 transcript in PBMCs was the 6 exon-spanning form, followed by IL-7d5 and IL-7d4; the same was true for the IL-7R transcript: the 8 exonspanning transcript accounted for 490% of all IL-7R transcripts, followed by IL-7Rd6 in PBMC samples from 15/15 NHPs (for time point 0, that is, before vaccination). RNA sequence analysis of the IL-7R from NHP PBMCs showed the presence of C in single-nucleotide polymorphism rs_6897932 (C/T). We could not detect any changes of IL-7 or IL-7R transcript patterns (Supplementary Figure S2 ) in PBMCs before BCG vaccination (time point 0), after BCG vaccination (week 27 after vaccination) or after challenge with virulent Mtb bacilli (week 43, that is, 4 weeks after Mtb challenge, data not shown).
Increased IL-7 protein expression in pulmonary tissues from NHPs vaccinated with rBCG As the number of individual NHPs in each group was rather small (n ¼ 6 per group), we are not in the position to make statements concerning increased survival. Pulmonary tissue, regional hilus LNs, axillary LNs and spleen tissue was harvested and processed for IL-7 RNA isoform and IL-7 protein expression. We could detect more IL-7 protein in situ in lung tissue from NHPs vaccinated with rBCG (group 2) when compared with the BCG (group 1) or control animals (group 3) (Figure 1a) . IL-7 protein expression was increased in lung lesions that exhibited macroscopic changes when compared with macroscopically nonaffected lung tissue (data not shown). In contrast, transforming growth factor-b (TGF-b) protein expression was significantly decreased in lung tissue from animals with rBCG vaccination. Representative examples of IL-7 and TGF-b protein expression in TB lung lesions are provided in Figure 1a . Examination of IL-17 in situ protein expression showed the strongest IL-17 expression in rBCG-vaccinated animals, followed by BCG-vaccinated and control animals ( Figure 1a, right panel) . At the end of the observation period (Figure 1b ) only 3/6 animals were alive from the control group, 2/6 NHPs who received BCG as a prime and 5/6 animas who received rBCG as the prime.
We examined serial sections, which had been stained for IL-7 protein in the lung also for IL-7 RNA expression patterns, as we showed previously that the monoclonal antibody used for staining recognizes at least three IL-7 isoforms, including IL-7d5. We could exclusively detect the 6 exon-spanning IL-7 (IL-7c) in lung tissue (Figure 1c ), LNs and spleen tissue in all specimens available at the end of the study period. Note that the monoclonal antibody used for IL-7 immunostaining would also recognize other IL-7 isoforms. As the IL-7 RNA analysis showed a uniform IL-7c (6 exon) expression, we can conclude that increased IL-7 protein expression is because of the full-length IL-7 protein. TGF-b expression appeared to be primarily associated with cells with morphology of tissue-resident macrophages as shown in Mtb-infected lung tissue from control animals ( Figure 1d) . A compilation for IL-7, TGF-b and IL-17 protein expression is provided in Figure 1e . Gene expression analysis in lung, axillary and hilus LN tissues showed decreased IL-10 and increased IL-17 gene expression as a typical feature in tissues from rBCG when compared with BCG-vaccinated animals (Supplementary Figure S3 ).
Next, we tested whether IL-7 or interferon-g (IFNwould increase IL-17 gene and protein expression in PBMCs from NHPs ( Figure 2 
Topology of sIL-7R in response to
Mtb infection Next, we tested for differential IL-7R splicing patterns in the lung, hilus or axillary LNs or in the spleen in the different NHP groups. We could not detect any differences in IL-7R splicing patterns between the different groups. Tissue specimens from NHPs exhibited the same IL-7R distribution pattern (see Figure 3) , depending on the anatomical localization. The dominant IL-7R transcript (up to 90%) is the sIL-7R lacking exon 6 (IL-7Rd6) in lung tissue. This situation is different in hilus LNs: IL7Rd6 transcripts account for B30% of the entire IL-7R transcript and for 47% (mean) in IL-7R transcripts in axillary LNs. In contrast, the full-length IL-7R constituted up to 85% in the spleen, followed by IL-7Rd6 and IL7Rd5/6 transcripts. PBMCs showed a uniform picture with 490% of the IL-7R transcript constituted by the 8 exon-spanning IL-7R. Examination of healthy human and NHP lung tissue revealed that the inverse IL-7Rc/ IL-7Rd6 ratio was not related to Mtb infection, and yet represented rather a physiological pattern of IL-7Rd6 transcripts in lung tissue. Measurement of sIL-7R or IL-7 in serum before and after Mtb infection did not show any differences (data not shown). Figure S5) as well as (CD3 þ ) CD8a-a and CD8a-b þ T-cell proliferation ( Figure 4 ) was analyzed at 2, 7 and 15 weeks after challenge with virulent Mtb bacilli. We did not observe differences in T-cell proliferation in CD4 or in CD8a-b þ T cells, but it IL-7 and IL-7 receptor in M. tuberculosis infection L Rane et al was observed in (CD3 þ ) CD8a-a þ T cells 7 weeks after Mtb challenge directed against the Mtb antigens Ag85B, PPD (purified protein derivative of Mtb) and BCG. This was not found to be true for the Ag85A antigen (Figure 4a ). In order to gauge for differences in rBCGvs BCG-induced immune responses, we incubated PBMCs from five individual naive NHPs for 5 days either with rBCG or with BCG (Supplementary Table S1 ). rBCG induced stronger TNF-a, IFN-g and IL-6 responses in 5/5 PBMC samples. We could not detect meaningful IFN-g production using intracellular cytokine staining directed against Ag85A/B (data not shown) in PBMCs after the challenge with viable Mtb.
Differences in T-cell proliferation
CD4 þ (Supplementary
Discussion
The two salient findings of the study are (1) increased IL-7 protein production in situ (lung tissue) from NHPs who received rBCG vaccination, which was associated with increased survival, and (2) that the sIL-7R represents the dominant transcript in lung tissue.
Although increased IL-7 production in situ may represent only one of the many factors in a very complex orchestration of immune-response molecules, it corroborates the notion that IL-7-driven immune responses lead to increased survival in a murine TB model. 16 IL-7 enhances and broadens the cellular immune repertoire in individuals suffering from chronic infections, 3 and similar mechanisms may also play a role in the NHP group vaccinated with rBCG.
IL-7 represents a T-cell survival factor without inducing strong proliferative responses when compared with IL-2. We could not show strong differences in antigenspecific peripheral T-cell proliferation in animals vaccinated with BCG, rBCG and in PBMCs from NHPs who received only saline (Figure 4) . The same was true concerning antigen-specific IFN-g production after challenge with Mtb (data not shown), suggesting that detection of antigen-specific immune responses in the peripheral circulation may not reflect the in situ situation, a situation that is appreciated in gauging antitumorspecific cellular immune responses: T-cell specificity mediating tumor regression in situ is very low in PBMCs and is not identical with the immunizing antigen. 29, 30 However, we were able to detect stronger induction of proinflammatory cytokines by rBCG vs BCG in PBMCs (Supplementary Table S1 ). A more proinflammatory milieu at the time of priming may drive quantitatively and qualitative different cellular immune responses with the capacity to home into Mtb-infected tissues. Not mutually exclusive, detection of Ag85A/B antigenspecific immune responses may simply not gauge biologically relevant cellular immune responses in the peripheral circulation. The only marked difference was an increased proliferation in response to Ag85B, PPD and BCG in the CD3 þ CD8a-a þ T-cell subset in the rBCGvaccinated group 7 weeks after challenge with Mtb. CD3 þ CD8a-a T cells represent a memory CD8 þ T-cell subset 31 that produce a different set of cytokines upon antigenic stimulation, 32 including TNF-a, which has also been reported to increase IL-7 production. IL-7 may In contrast, supernatants from IL-7-stimulated cells showed IL-17a and IFN-g production. IL-17a production in nonstimulated PBMCs was not detectable, and 2/5 nonstimulated PBMC cultures exhibited 5 pg IFN-g per ml that was subtracted from the IL-7-induced IFN-g production.
IL-
promote expansion of this particular memory T-cell population. 33, 34 One of the potential 'clinical benefits' of IL-7 is that most Treg cells do not express the IL-7R; 35, 36 IL-7 elaborated in situ may therefore support anti-Mtb cellular immune responses instead of activating suppressive immune cells with immune-regulatory functions as it has been shown in a murine cancer model. 37 We could not detect differences in Treg cells between rBCG-and BCG-vaccinated NHPs in PBMCs, yet PBMCs from 2/6 control animals showed increased Tregs after Mtb infection (Supplementary Figure S4) . Strong IL-7 expression in situ may, via Smad7 increase, counteract TGFbproduction, 38 which is responsible for tissue remodeling and subsequent reduced pulmonary capacity of oxygen exchange (reviewed in Chapman 39 ) This notion has been consolidated in this report as NHPs vaccinated with rBCG exhibited increased IL-7 protein expression in situ (Figures 1a and e) that correlated with decreased TGF-b protein in Mtb-infected lung tissue. Decreased TGF-b production, as a result of increased IL-7 at the site of infection, may also lead to decreased expansion of regulatory T cells. Infection with viral pathogens, associated with increased TGF-b production, for example hepatitis C virus, leads to Treg induction and impaired protective host immune responses. 40 In addition, IL-7 has been shown to expand antigen-specific IL-17-producing T cells in a murine experimental autoimmune encephalomyelitis model. 41 We show in the current report detection of increased IL-17 production in rBCG-vaccinated NHPs when compared with BCG-vaccinated or control animals. IL-17 has been shown to confer protection against Mtb in murine model. 42 This is partially independent of IFN-g and appears to be associated with IL-17-driven granuloma formation. 42, 43 Immune protection in Mtb infection is certainly multifaceted; for example, we show here that IL-7 decreased in NHP PBMCs IL-10 and Foxp3 gene expression, whereas only IL-7, yet not IFN-g yielded increased IL-17 gene and protein expression in PBMCs from 5/5 NHPs (Figure 2) . Thus, increased IL-17 protein detection in situ and IL-7-driven IL-17 production in vitro suggest that the 6 exonspanning IL-7 protein mediates beneficial effects in Mtb infection via IL-17 induction.
If IL-7 increases in situ IL-17a and decreases TGF-b production, which factors induce IL-7 production in situ and why is IL-7 protein differentially expressed in rBCGvs BCG-vaccinated animals? A candidate for IL-7 augmentation is IFN-g, which has been shown to increase IL-7 production in epithelial cells, 44 ,45 although we could not, at the time of blood draw, show increased IFN-g production in Ag85A/B-specific PBMCs after challenge with Mtb, nor could we detect that IFN-g drives IL-7 expression in PBMCs. Only monocytes would 
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be candidates for IL-7 production in PBMCS-and this may not be relevant in situ. Thus, lung-resident macrophages, epithelial and endothelial cells may be the prime targets for IFN-g-mediated effects. This has recently been suggested in a murine TB model study: IFN-g-responsive non-hematopoietic cells appear to be responsible for mediating anti-Mtb protective immune responses. 46 A striking difference in IL-7 RNA expression pattern in NHP analysis is the dominant IL-7c transcript in 15/15 NHP PBMC samples when compared with human PBMCs 8 that exhibit a different pattern with a dominant IL-7d4 transcript (see Supplementary Figures S1 and S2) . The uniform IL-7c transcript pattern in samples from NHPs has also been observed in lung, LN and spleen tissue and does not appear to be associated with a certain proinflammatory environment as 15/15 NHP PBMC samples showed the same pattern before BCG (and also after Mtb infection; see Supplementary Figures  S1 and S2) .
The other striking finding is that IL-7Rd6 represents the dominant IL7 isoform in lung tissue. This appears to be rather associated with a tissue-specific IL-7R expression pattern as lung tissue from healthy NHPs (or a human) display the same pattern: up to 90% of the IL-7R transcripts is IL-7Rd6 (which is partially reversed in LNs, PBMCs and spleen that show the same dominant expression pattern of the 8 exon IL-7R, see Figure 3) . A recent report, using serum samples from individuals with HIV infection, showed that the sIL-7R inhibits the biological function of IL-7. 22 Such a 'dampening' of IL-7 actions may be required where the immune system, via the airway system, is exposed to the environment. Reduced immune responsiveness at the pulmonary interface may be instrumental to avoid IL-7-driven autoimmune immune responses. Hence, there may be dual effects of IL-7. It may productively enhance immune responses against pathogens or transformed cells, but it may also promote cellular autoimmune responses. 47 A physiological sIL-7R in lung tissue may be able to curb unwanted immune reactivity by neutralizing IL-7 protein elaborated in situ-which would be able to promote survival of autoimmune-reactive T cells. IL-7Rd6 may therefore represent a tissue-specific IL-7 antagonist, similar to the IL-4d2 isoform that, predominantly expressed in the airway system (also in response to Mtb infection), antagonizes IgE production in B cells and prostaglandin 2 secretion in monocytes 26 and may be associated with prediction of treatment responses in TB. 24 Several limitations apply for the NHP model. NHP physiology may be different when compared with the humans, which is evident based on the differential IL-7 RNA spicing pattern in PBMCs. 7, 8 IL7c is the dominant transcript in NHP PBMCs, whereas IL-7d4 is the dominant transcript in human PBMCs. Human and NHP PBMCs show a similar composition of immune cells, except for Tregs and CD8a-a þ T cells. 32 However, these cell types do not account for IL-7 production as 
only B cells, CD14 þ monocytes or dendritic cells are sources for IL-7 RNA production in PBMCs. 48, 49 It is also evident that the study of PBMCs for IL-7 or IL-7R RNA transcripts does not reflect the situation in situ, as we were able to describe a reverse ratio of IL-7Rc versus the sIL-7Rd6 in lung tissue versus spleen/PBMCs (see Figure 3 ) and different IL-7 ratios in axillary and hilus LNs. The 'gradients' in the IL-7R RNA patterns (IL-7Rc/ IL-7d6) appear to reflect either a tissue-related expression pattern or, not mutually exclusive, the result of immune cell infiltration into hilus and axillary LN stations. A variety of cells express the IL-7R, and the IL-7R splicing pattern may therefore be different. 32 Maximal differences for human IL-7R haplotype expressions have been identified in dendritic cells, 50 where the ratio of the IL-7R/receptor for thymic stromal lymphopoietin is crucial for Treg cells if the subsequent T-cell response shows a Th1 or a Th2 profile. Thus, subtle differences in immune cell infiltration may impact greatly on the detected IL-7 and IL-7R splicing patterns. Only specific monoclonal reagents, capable of differentiating between IL-7d6 and IL-7Rc, will in future studies be able to address the questions of which cells are responsible for IL-7Rd6 or IL-7Rc production and expression.
In summary, this report consolidates that alternative splicing of cytokines represents a physiological mechanism to create diversity and tissue/organ-specific cytokine splicing, patterns that could be explored for future biological therapy.
Materials and methods
NHPs and biological samples
In all, 15 female rhesus macaques (Macaca mulatta) of Chinese origin, all approximately 3 years old, were divided into three groups and immunized with different TB vaccines, followed by a challenge with Erdmann's strain of Mtb (500 CFU by intratracheal installation). Six animals received the BCG vaccine strain (SSI1331, group 1), and six animals received rBCG, which expressed perfringolysin to enable endosomal escape and access to the cytosol independent of the pH, along with a fusion protein of Ag85A, Ag85B and TB10.4 (group 2). 51 Both groups received an adenoviral boost (adenovirus 35, which also expressed the Mtb Ag85-Ag85b-Tb10.4 fusion protein) at weeks 15 and 27 after the prime: groups 1 and 2 different therefore only concerning the prime. Group 3 animals (the control group, initially three) received only saline, and three additional animals were added to this group before the Mtb challenge week (39 after the prime, virulent Mtb Erdman strain). Animals were captive bred and experiments were performed at the Astrid Fagraeus Laboratory and at the Biomedical Primate Research Centre, (Rijswijk, The Netherlands). The work was approved by the local ethical committees (protocol DNR238/2006-54 and DEC no. 551).
PBMC previous vaccination (prime), before and after the Mtb challenge were harvested to analyze differential IL-7 and IL-7R spliced variants. PBMCs were harvested from NHPs by venipuncture by a standard ficoll procedure and frozen in liquid nitrogen until analysis. Tissues from animals that succumbed after Mtb challenge (lung tissue with macroscopic and without macroscopic signs of inflammation, pulmonary hilus LNs, axillary LNs and spleen) were placed immediately after necropsy in RNAlater, followed by RNA extraction and complementary DNA (cDNA) preparation and analyzed for IL-7 and IL-7R RNA as described in detail below. Note that we accessed and processed only tissues from NHP that reached the fixed end point by protocol and not those animals that reached a premature humane end point because of severe TB disease.
Sample processing
PBMCs were recovered, cells were counted and subjected to RNA extraction using the RNeasy mini kit no. 74104 spin protocol, followed by the column DNase digestion step (Qiagen Inc., Hilden, Germany). RNA concentration was measured using a biophotometer. cDNA was transcribed using the Oligo-dt protocol from Superscript III first strand cDNA synthesis kit no. 18080-400 (Invitrogen Inc., Carlsbad, CA, USA). cDNA was stored at À20 1C and used for PCR analysis.
Tissue sections were preserved using RNAlater solution (Qiagen Inc.), and RNA was extracted using the Ribopure kit no. AM 1924 (Ambion Inc., Austin, TX, USA) and processed with an RNase free DNAse kit (Qiagen Inc.). RNA was reverse transcribed using the superscript III first strand synthesis kit.
PCR was performed using IL-7 and IL-7R primers to obtain full-length transcripts of IL-7 and IL-7R. Expression levels of different IL-7R isoforms were studied by analyzing transcripts using exon 4 forward and exon 8 reverse primers for better separation of amplified products. RNA quality of each of the samples was evaluated by amplifying samples for b-actin transcripts. IL-7 and IL-7R cDNA transcripts were amplified using PCR Taq polymerase, recombinant no. 10342-046 (Invitrogen Inc.); 5 U of Taq polymerase enzyme was added in each reaction. Both IL-7 and IL-7R amplifications were performed in 30 ml reaction volume. A total of 25 pM of each primer was taken in respective reaction along with 12 mM of dNTP mix and 45 mM of MgCl 2 . The amount of total cDNA subjected for PCR amplification of IL-7 and IL-7R transcript varies as the concentrations of the RNA isolates differed in each sample; 7 ml of total cDNA was used as template in all reactions. All reactions were initiated by denaturation at 94 1C Agar gel and Agilent LabChip analysis for mRNA splicing PCR products were first analyzed on an 1% agarose gel no. 15510-027 (Invitrogen) using GelRed (Biotium Inc., Hayward, CA, USA) and amplified products were compared with Gene Ruler DNA ladder mix no. SM0331 (Fermentas Life Sciences, Leon-Rot, Germany). Representative bands were selected for sequencing confirmation. PCR product (1 ml) from each sample was also analyzed IL-7 and IL-7 receptor in M. tuberculosis infection L Rane et al using the Agilent LabChip DNA 1000 kit no. 5056-4449 (Agilent Technologies). Time-corrected area parameters from each band were used to compare expression level of each IL-7 or IL-7R isoform in total (IL-7 or IL-7R) transcript expression within the sample.
Cloning and sequencing
Selected bands from IL-7 and IL-7R PCR products were extracted from the agarose gel and purified using the QIAquick gel extraction kit no. 28706 (Qiagen). This product was immediately cloned in pCR 2.1 TOPO vector no. K4500-01 (Invitrogen), then transformed into One Shot DH5a-T1 Competent Cells no. K4520-01 (Invitrogen) and harvested according to the supplier's instructions.
These isolated plasmids were subjected to a PCR sequencing reaction using the Big Dye Terminator V.3.1 Cycle sequencing kit no. 4337455 (Applied Biosystems, Foster City, CA, USA) according to the supplier's instructions. Sequencing was performed using an ABI 3130 Genetic analyzer (Applied Biosystems). DNA sequences were examined using Chromas Lite 2.01 software (Technelysium Pty Ltd., Helensville, QLD, Australia) and aligned with full-length transcript sequences that allowed to control results from the Agar gel electrophoresis and the Agilent chip results.
Immunohistochemistry of frozen lung tissue sections Pulmonary biopsies were obtained from both (macroscopically affected) lung lesions and unaffected lung tissue parts of the Mtb-infected lung from rBCG AFRO-1-primed (n ¼ 6), BCG-primed (n ¼ 6) and unvaccinated control (n ¼ 6) animals. AFRO-1 is a recombinant BCG (Bacille Calmette Guerin) strain, developed from the AERAS foundation (Washington, DC, USA), which expresses perfringolysin and the Mtb antigens TB10. 4 and Ag85A/B. Cryopreserved tissue were embedded in optimal cutting temperature compound (Tissue-TEK, Sakura, Torrance, CA, USA) and cut into 8 mm thick sections before fixation in 4% formaldehyde (Sigma, Stockholm, Sweden). Immunohistochemistry was performed according to the ABC-method including development of positive staining using a diaminobenzidine substrate (Vector Laboratories, Burlingame, CA, USA) and hematoxylin for nuclear counterstaining. Immunohistochemical stainings were assessed at the single-cell level in situ by quantitative computerized image analysis using a DMR-X microscope, the image analysis system Quantimet Q5501W (Leica Microsystems, Wetzlar, Germany) and a Qwin 550 software program (Leica Imaging Systems, Wetzlar, Germany). Protein expressions of cytokines are presented as ACIA (acquired computerized image analysis) score. The ACIA score was determined as final % positively stained area in the total relevant cell area Â mean intensity of the positive staining. The complete tissue sections were scanned and had a mean size of 3 Â 10 6 mm 2 including, that is, 10-40 microscopic fields. The primary antibodies used were IL-7 (clone B-N18) from Diaclone (Besancon, France), TGF-b from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA) and anti-IL-17 (clone 41802) from R&D Systems Inc. (Minneapolis, MN, USA) . Biotinylated secondary antibodies, goat anti-mouse IgG and swine anti-rabbit F(ab 0 ) 2 respectively, were purchased from Dako (Glostrup, Denmark).
Representative immunohistochemical results from the TB lung lesions are shown and a nonparametric KruskalWallis test (GraphPad Prism-4, GraphPad software Inc., La Jolla, CA, USA) was used to calculate indicated P-values. A P-value between 0.01 and 0.05 was considered significant (*), whereas a P-value 40.05 was considered not significant. We could not study IL-7R protein expression in situ as the available monoclonal antibodies did not work on the tissue sections; we could also not conclude whether antibodies directed against the IL-7R react only against the cell-bound form or whether they recognize the sIL-7R protein also.
T-cell assays
Heparin blood was obtained from NHPs as described in detail earlier and stimulated for 5 days in the presence of different recombinant antigens including Ag85A, Ag85B and TB10.4 (see ref. 51 ) PPD as well as BCG1331 were also used as stimuli, medium alone served as the negative control, and SEA/SEB as the positive control. Red blood cells were lysed at day 7 and T-cell proliferation was measured as described defined by blast formation using forward and sideward scatter analysis by flow cytometry. We analyzed antigen-specific proliferation in (CD3 þ ) CD4 þ T cells, in (CD3 þ ) CD8a-a, as well as in CD8a-b þ T cells. 32 Data are represented as the median percentage of the proliferation index as described. Analysis of Treg cells was performed as described using antibodies directed against CD3, CD4, CD25, Foxp3 and the IL-7R (CD127), 32 and intracellular cytokine staining for Ag85A/B responses in PBMCs was performed as described in detail earlier. 51 Stimulation of PBMCs with rBCG or BCG was performed in AIM-V medium, and cell culture supernatants were harvested after 5 days and tested for Th1/Th2 cytokine production (IFN-g, TNF-a, IL-6, IL-4, IL-5 and IL-2) using a high-sensitivity detection assay for NHP cytokines (CBA assay, BD, distributor Stockholm, Sweden).
Quantitative PCR and enzyme-linked immunosorbent assay PBMCs (1 million) from five different NHPs were cultured using serum free AIM-V medium (87-0112DK, Invitrogen, Paisley, UK) in 24-well plates in duplicates with the following conditions: 100 ng ml -1 recombinant hIL7 (a generous gift from Michel Morre, Cytheris, Paris) and 100 U ml -1 IFN-g (R&D, Abingdon, UK) or phosphatebuffered saline as a control. Supernatants and cells were collected after 5 days of incubation to determine gene expression by quantitative PCR in PBMCs, and supernatants were tested for the presence of IL17a (Diaclone, Nordic Biosite, Täby, Sweden), IFN-y, and IL-7 (both from Biosite) according to the manufacturer's instructions.
Total RNA from cells or tissues was extracted using RNeasy Mini Kit (Qiagen) and transcribed into cDNA, followed by gene expression analysis using TaqMan gene expression assays using an ABI7900 real time instrument (Applied Biosystem). The following assay IDs were used: IL-7, Rh02621732_m1; IL-2, Rh027889780_m1; IL-10, Rh_02621709_m1; IL-15, Rh_02621777_m1; IL-17, Rh_02621750_m1; IFN-g, Rh_02788577_m1; Foxp3, Rh_02788830_m1 and b-actin, Rh_03043379_gH. Gene expression data were analyzed by the DDCT method (delta delta CT, comparative CT method) to relatively quantify gene expression in IL-7-and IFN-g-stimulated PBMCs compared with unstimulated cells. Tissue gene expressions in rBCG-vaccinated NHPs were compared with the corresponding tissues samples from the BCGvaccinated group.
